Text Size
- News Releases
- What's New
- 02 Oct
- Chugai’s Enspryng Launched in Taiwan as First Indication for Neuromyelitis Optica Spectrum Disorder (NMOSD)
- 25 Sep
- Chugai Obtains Approval for Additional Indication of Actemra for Cytokine Release Syndrome Induced by Cancer Therapy in Japan
- 25 Sep
- Chugai Obtains Regulatory Approval for Phesgo, the Fixed-Dose Subcutaneous Combination of Perjeta and Herceptin for HER2-Positive Breast and Colorectal Cancer
- 06 Sep
- FDA Accepts Application for Chugai’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
- Share this site
